Zai Lab Limited (ZLAB)
NASDAQ: ZLAB · Real-Time Price · USD
35.63
+1.32 (3.85%)
At close: Aug 13, 2025, 4:00 PM
35.64
+0.01 (0.03%)
After-hours: Aug 13, 2025, 5:11 PM EDT
Zai Lab Employees
Zai Lab had 1,869 employees as of December 31, 2024. The number of employees decreased by 306 or -14.07% compared to the previous year.
Employees
1,869
Change (1Y)
-306
Growth (1Y)
-14.07%
Revenue / Employee
$228,892
Profits / Employee
-$113,708
Market Cap
3.92B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ZLAB News
- 8 hours ago - Zai Lab Establishes Oncology Scientific Advisory Board - Business Wire
- 5 days ago - Zai Lab Limited (ZLAB) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates - Business Wire
- 4 weeks ago - Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025 - Business Wire
- 6 weeks ago - Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer - Business Wire
- 2 months ago - Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025 - Business Wire
- 2 months ago - Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting - Business Wire
- 2 months ago - Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting - Business Wire